Navigation Links
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
Date:12/1/2009

dent for Business Development added: "Our research and preclinical development teams have done an excellent job in advancing the program since January of this year. Bayer Schering Pharma's early option exercise is a recognition of Micromet's development capabilities and confirms the promise of our BiTE antibody platform."

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Forward-Looking Statements

This release contains certain forward-looking
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
2. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
3. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
4. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
5. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
6. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
7. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... BRUSSELS , Sept. 1, 2015 /PRNewswire/ ... Brussels: UCB) today announced top-line results from the ... with Teriparatide in postmenopaUsal women with osteoporosis at ... therapy). The study (NCT01796301) met the primary endpoint, ... romosozumab in the percent change of total hip ...
(Date:9/1/2015)... WAYNE, N.J. , Sept. 1, 2015 ... II CS-7s Computed Radiography (CR) system, designed to deliver ... practices. By utilizing the same Control Station as the ... is assured with an upgrade path from CR to ... patient imaging to help improve workflow with unparalleled reliability ...
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. Daniel K. ... Michael C. Burgess , M.D., and Joe ... st Century Cures Act, bipartisan legislation in support ... the United States Senate. UT ... department chairs, center directors, and leading researchers – joined ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5
... a primary biliary cirrhosis patient,has the biomarker of ... Mayo Clinic,researchers have found that first-degree relatives (i.e., ... (PBC) are,more likely to have the biomarker of ... information, physicians could screen and assess first-degree,relatives of ...
... Va., Sept. 10 The following letter is,being released ... shareholders: Dear Fellow Shareholders: The past 12 ... The U.S. Food and Drug Administration (FDA) granted us ... trial with our cancer drug,Multikine(R) and also granted Multikine ...
Cached Medicine Technology:New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families 2CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 5
(Date:9/2/2015)... ... September 02, 2015 , ... Canopy Partners, a ... to the Inc. 5000 List, an independent ranking of the fastest- growing ... years, and this achievement puts Canopy in rarefied company. Over the years, this ...
(Date:9/2/2015)... ... September 02, 2015 , ... Traveling to the Caribbean can be ... magnificent flora and fauna. , Lifestyle Holidays Vacation Club knows that ... make travelers experience that much better, Lifestyle Holidays Vacation Club has put together its ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate Cancer ... affects more than 233,000 men each year in the United States. , Prostate cancer ... non-skin cancer in America, affecting 1 in 7 men. One new case occurs every ...
(Date:9/1/2015)... ... 2015 , ... Earth Brands, ( http://www.earthbrands.com ) a comfort-meets-fashion ... who buys an Earth Brand shoe will be given an opportunity to plant ... Future, a nonprofit dedicated to planting more trees. Earth Brands products represent contemporary ...
(Date:9/1/2015)... ... September 01, 2015 , ... Stress comes ... created from everyday life changes can lead to very serious, life-altering events. Fortunately ... coping with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic doses ...
Breaking Medicine News(10 mins):Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3
... say finding suggests alternate vision routes in the brain , , ... of second sight: Scientists report that a blind man in ... even though he has no conscious sensation of seeing the ... that the human brain has ways of processing vision beyond ...
... patients with autoimmune diseases like lupus and rheumatoid arthritis ... too, according to a new report in the ... these cells are maintained in an ,off, state, perhaps ... true predecessors of the self-attacking cells prevalent in lupus ...
... woes ratchet up mental health problems already more common this ... --Sagging spirits, sagging economy. , That,s the holidays this ... -- the usual melancholy compounded by the highest jobless rate ... "Mental health problems are common and spike more often during ...
... Eve , ... Terre Haute, Ind. (PRWEB) December 22, 2008 -- Fleschner, Stark, Tanoos ... provide free transportation to those who can,t drive or feel they don,t have ... Cab Ride Home program will be available from 10 p.m. on Wednesday, December ...
... two proteins which work in tandem in the brain,s blood ... do the proteins lessen blood flow in the brain, but ... able to remove amyloid beta, the protein that builds up ... disease. , The work, described in a paper published online ...
... pressures can be overcome with honest approach to food, ... The holiday season can be especially difficult for overweight ... eating habits and cope with widely held misconceptions, according ... people feel self-conscious about what they wear and what ...
Cached Medicine News:Health News:'Blind' Man Navigates Obstacle Course Without Error 2Health News:Potential autoimmunity-inducing cells found in healthy adults 2Health News:Blue and Broke for the Holidays 2Health News:Blue and Broke for the Holidays 3Health News:Blue and Broke for the Holidays 4Health News:Fleschner, Stark, Tanoos & Newlin to Offer Free Terre Haute Cab Rides on New Year's Eve 2Health News:Fleschner, Stark, Tanoos & Newlin to Offer Free Terre Haute Cab Rides on New Year's Eve 3Health News:Two cardiovascular proteins pose a double whammy in Alzheimer's 2Health News:Two cardiovascular proteins pose a double whammy in Alzheimer's 3Health News:Two cardiovascular proteins pose a double whammy in Alzheimer's 4Health News:For the Obese, Holiday Tables Serve Platefuls of Doubt 2
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Gold radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
... The tipless balloon design allows the ureter ... A radiopaque marker at the base of ... extent of ureteral dilation. Supplied sterile in ... includes:, Pin Vise Handle (plastic), Straight Safety ...
Used retrograde to dilate the ureter and establish a conduit for a flexible ureteroscope. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: